Coherus gets Inter Partes Review of Humira patent

17 May 2016

US biosimilars firm Coherus BioSciences (Nasdaq: CHRS) today announced that it has received a favorable decision from the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark office instituting Coherus’ petition for Inter Partes Review (IPR) of AbbVie’s (NYSE: ABBV) mega-blockbuster arthritis drug Humira (adalimumab).

The review relates to AbbVie’s US Patent 8,889,135 directed to a dosing regimen in which 40mg of Humira is administered subcutaneously every 13 to 15 days to treat rheumatoid arthritis. IPRs allow anyone to challenge the validity of a patent far more cheaply and quickly than going through the US federal court system.

Coherus has shown a “reasonable likelihood” that it will win the challenge, the Patent Trial and Appeal Board said in an opinion Tuesday instituting a formal review of the patent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK